The diagnostic value of serum trefoil factor 3 and pepsinogen combination in chronic atrophic gastritis: a retrospective study based on a gastric cancer screening cohort in the community population
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Serum Trefoil Factor 3 (TFF3) shows promise as a non-invasive biomarker for chronic atrophic gastritis (CAG). Combined with pepsinogen ratio (PGR), TFF3 effectively predicts CAG, particularly in H. pylori-negative individuals.
Area Of Science
- Gastroenterology
- Biomarker Discovery
- Oncology
Background
- Chronic atrophic gastritis (CAG) is a significant precursor to gastric cancer (GC).
- Current diagnostic methods for CAG lack reliable non-invasive markers for community screening.
- There is a need for effective biomarkers for early detection of CAG.
Purpose Of The Study
- To identify a non-invasive biomarker for the community screening of CAG.
- To evaluate the diagnostic significance of serum Trefoil Factor 3 (TFF3) for CAG.
- To assess the combined diagnostic value of TFF3 and pepsinogen (PG) in different Helicobacter pylori (H. pylori) infection states.
Main Methods
- A total of 540 individuals were enrolled in test (385) and validation (155) sets.
- Serum TFF3 levels were measured and compared between CAG and chronic superficial gastritis (CSG) groups.
- Receiver operating characteristic (ROC) curve analysis was used to evaluate diagnostic performance of TFF3 alone and in combination with the ratio of PGI to PGII (PGR).
Main Results
- Serum TFF3 levels were significantly higher in CAG patients (27 ng/ml) compared to CSG patients (19.61 ng/ml) (P < 0.001).
- TFF3 alone demonstrated a sensitivity of 0.529, specificity of 0.87, and AUC of 0.739 for CAG diagnosis.
- The combination of TFF3 and PGR achieved an AUC of 0.755 and specificity of 0.825, showing good predictive value, especially in H. pylori-negative individuals.
Conclusions
- Serum TFF3, particularly when combined with PGR, serves as an effective predictor of CAG.
- This combination shows particular promise for non-invasive CAG screening in H. pylori-negative populations.
- TFF3 represents a potential non-invasive biomarker for early detection and management of CAG.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Location of Pain:...
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...